Nutriband Inc. (NASDAQ: NTRB), in collaboration with Kindeva, has achieved a milestone in the development of Aversa Fentanyl by successfully scaling up its commercial manufacturing process. This development is pivotal as Aversa Fentanyl aims to be the world's first abuse-deterrent opioid patch, integrating Nutriband's AVERSA technology with Kindeva's FDA-approved fentanyl patch. The collaboration leverages Kindeva's expertise in drug-device combinations and its U.S.-based transdermal facility to produce the patch.
The significance of this advancement lies in its potential to mitigate the opioid crisis by preventing the abuse, misuse, and accidental exposure of fentanyl, a potent opioid with high abuse potential. With the next steps involving the production of clinical supplies and submission of an Investigational New Drug application for a human abuse liability study, Aversa Fentanyl is on a path that could redefine opioid therapy. Nutriband projects peak U.S. sales between $80 million and $200 million, highlighting the commercial and therapeutic potential of this innovation.
This development is not just a breakthrough for Nutriband and Kindeva but also represents a critical step forward in the fight against opioid abuse. By offering a solution that deters abuse while providing pain relief, Aversa Fentanyl could significantly impact the pharmaceutical industry and public health, offering a safer alternative to traditional opioid treatments.
